Clinical Trial Update: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial exploring APG-2575 as monotherapy or in combination with lenalidomide or DXMS in relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• APG-2575
• DXMS
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN